×
About 4,240 results

ALLMedicine™ Hemophilia A Center

Research & Reviews  1,304 results

Correction of a Factor VIII genomic inversion with designer-recombinases.
https://doi.org/10.1038/s41467-022-28080-7
Nature Communications; Lansing F, Mukhametzyanova L et. al.

Jan 22nd, 2022 - Despite advances in nuclease-based genome editing technologies, correcting human disease-causing genomic inversions remains a challenge. Here, we describe the potential use of a recombinase-based system to correct the 140 kb inversion of the F8 ge...

Prophylaxis Regimen for Hemophilia A Patients
https://clinicaltrials.gov/ct2/show/NCT05036278

Jan 21st, 2022 - Researchers are looking for a better way to treat people who have hemophilia A. Hemophilia A is a genetic bleeding disorder that is caused by the lack of a protein in the blood called "clotting factor 8" (FVIII). FVIII is naturally found in the bl...

Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors
https://clinicaltrials.gov/ct2/show/NCT05145127

Jan 20th, 2022 - Study B7841007 is an open-label extension study to assess the long-term safety, tolerability, and efficacy of prophylaxis treatment with marstacimab in participants who did not require "Early Termination" from the Phase 3 Study B7841005. Approxima...

Thrombin generation for monitoring hemostatic therapy in hemophilia A: a narrative review.
https://doi.org/10.1111/jth.15640
Journal of Thrombosis and Haemostasis : JTH; Verhagen MJA, Valke LLFG et. al.

Jan 17th, 2022 - Patients with severe hemophilia A (HA) have an increased risk of spontaneous and trauma-related bleeding due to a congenital absence of factor VIII (FVIII). Most severe HA patients use prophylactic FVIII concentrate which effect can be monitored w...

see more →

Guidelines  1 results

International recommendations on the diagnosis and treatment of patients with acquired ...
https://doi.org/10.3324/haematol.2008.001743
Haematologica Huth-Kühne A, Baudo F et. al.

Apr 2nd, 2009 - Acquired hemophilia A (AHA) is a rare bleeding disorder characterized by autoantibodies directed against circulating coagulation factor (F) VIII. Typically, patients with no prior history of a bleeding disorder present with spontaneous bleeding an...

see more →

Drugs  58 results see all →

Clinicaltrials.gov  110 results

Prophylaxis Regimen for Hemophilia A Patients
https://clinicaltrials.gov/ct2/show/NCT05036278

Jan 21st, 2022 - Researchers are looking for a better way to treat people who have hemophilia A. Hemophilia A is a genetic bleeding disorder that is caused by the lack of a protein in the blood called "clotting factor 8" (FVIII). FVIII is naturally found in the bl...

Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors
https://clinicaltrials.gov/ct2/show/NCT05145127

Jan 20th, 2022 - Study B7841007 is an open-label extension study to assess the long-term safety, tolerability, and efficacy of prophylaxis treatment with marstacimab in participants who did not require "Early Termination" from the Phase 3 Study B7841005. Approxima...

Study to Learn More About the Safety of Drug Jivi Over a Long Period of Time in Previously Treated Patients With Hemophilia A (Bleeding Disorder Resulting From a Lack of FVIII) Who Are Receiving Ji...
https://clinicaltrials.gov/ct2/show/NCT04461639

Jan 11th, 2022 - In this observational study researchers want to learn more about the safety of drug Jivi over a long period of time. Jivi (generic name: Damoctocog alfa pegol) is an approved blood clotting Factor VIII (FVIII) medication for the treatment of hemop...

A Study to Evaluate Overall Health, Physical Activity, and Joint Outcomes in Participants With Severe or Moderate Hemophilia A Without Factor VIII Inhibitors on Emicizumab Prophylaxis
https://clinicaltrials.gov/ct2/show/NCT05181618

Jan 6th, 2022 - Study MO42623 is a Phase IV, multicenter, open-label, three cohort study designed to evaluate the impact of emicizumab prophylaxis on overall health, physical activity, and joint outcomes in participants aged ≥13 and <70 years with severe hemophil...

Study to Gain More Information on How Safe and Effective Jivi Works in Patients With Severe Hemophila A (Post-marketing Investigation)
https://clinicaltrials.gov/ct2/show/NCT04085458

Jan 3rd, 2022 - The goal of this study is to give gather more information on how safe and well Jivi works in patients with severe hemophilia A. Jivi has been approved by various regulatory agencies, including the FDA, Health Canada, Japanese Health Authority and ...

see more →

News  223 results

Bispecifics Prove to Have Intriguing Role in Lung Cancer
https://www.onclive.com/view/bispecifics-prove-to-have-intriguing-role-in-lung-cancer

Jul 30th, 2021 - Bispecific antibodies have become an interesting new class of agents in the lung cancer pipeline, most recently with the developments of amivantamab-vmjw (Rybrevant), zenocutuzumab (MCLA-128), and tarlatamab (AMG-757), according to Giorgio V. Scag...

2019 Biologics Recalls | FDA
https://www.fda.gov/vaccines-blood-biologics/recalls-biologics/2019-biologics-recalls

Date Notification Brand Name Product Description Reason/Problem Company October 3, 2019 Important Drug Information - Humate-P [Antihemophilic Factor/von Willebrand Factor Complex (Human)] Lots of All Fill Sizes (600, 1200, 2400 IUs) distributed by...

Elevated factor VIII troughs can lead to a higher proportion of zero bleeds in hemophilia
https://www.mdedge.com/hematology-oncology/article/240888/bleeding-disorders/elevated-factor-viii-troughs-can-lead-higher
Mark S. Lesney, PhD

Jun 1st, 2021 - Rurioctocog alfa pegol prophylaxis was linked to fewer bleeding episodes in people with hemophilia A when it targeted higher levels of factor VIII (FVIII) troughs, according to a report published in Blood (2021;137[13]:1818-27). Earlier studies de.

Joint pain in patients with hemophilia may be neuropathic
https://www.mdedge.com/hematology-oncology/article/237009/bleeding-disorders/joint-pain-patients-hemophilia-may-be
Neil Osterweil

Mar 10th, 2021 - Nearly one-third of persons with hemophilia had neuropathic pain or altered central pain mechanisms, investigators in a small study found. Among 30 patients with hemophilia, 9 (30%) had scores of 4 or greater on the 10-point Diabetic Neuropathy 4.

Bleeding Disorder Diagnoses Delayed by Years in Girls and Women
https://www.medscape.com/viewarticle/947192

Mar 10th, 2021 - Diagnosis of bleeding disorders in girls and women can lag behind diagnosis in boys and men by more than a decade, meaning needless delays in treatment and poor quality of life for many with hemophilia or related conditions. "There is increasing a...

see more →